Livzon Pharma unit gets China NMPA approval for 11.25 mg three-month leuprorelin microspheres

Shanghai Livzon received NMPA clearance to market leuprorelin acetate microspheres injection 11.25 mg, adding a three-month specification to its existing 3.75 mg and 1.88 mg versions. R&D spending for the three-month formulation was about RMB 94.0548 million.